Subjects
Cancer
CANCER
Inpatients and outpatients being treated for mCRC at the Cancer Institute of Hospital Ariake who met the eligibility criteria without meeting any of the exclusion criteria were included. Topical aluminum chloride was applied one week prior to the start of regorafenib treatment. Regorafenib 120 mg, a lower starting dosage than normally prescribed in the study center’s routine clinical practice, was administered once daily for 21 days in each 28-day cycle. The inclusion and exclusion criteria are listed in eTable 1 [see Additional file 
CONSORT diagramThe 30% aluminum chloride formulation used in the present study was dispensed in the hospital. The method of dispensing the drug is shown in eTable 4 [see Additional file 